Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Ten of 11 analysts rate Stoke Therapeutics a buy, while one rates it a sell. The average 12-month price target is $44.25, above the reported opening price of $29.20.
• Financial results remain pressured: Stoke reported a quarterly loss of $0.93 per share, missing estimates by $0.13, despite revenue of $9.32 million exceeding expectations. Analysts project a full-year loss of $3.52 per share.
• Insiders reduced their holdings: Insiders sold 32,916 shares worth approximately $1.03 million during the last quarter, although some institutional investors initiated or expanded positions in the company.

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $44.25.

A number of research analysts have issued reports on STOK shares. Weiss Ratings restated a "sell (d)" rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Chardan Capital reiterated a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research note on Friday, August 21st. They issued an "overweight" rating and a $40.00 price target for the company. Canaccord Genuity Group reduced their price target on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Tuesday, August 4th. Finally, Wedbush raised their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 4th.

Stoke Therapeutics Stock Up 4.1%

NASDAQ STOK opened at $29.20 on Wednesday. Stoke Therapeutics has a 12-month low of $20.32 and a 12-month high of $40.22. The firm's 50 day moving average is $30.46 and its 200-day moving average is $31.74. The company has a market capitalization of $1.88 billion, a PE ratio of -8.74 and a beta of 1.23.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, sell-side analysts expect that Stoke Therapeutics will post -3.52 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 7,176 shares of the company's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the sale, the insider directly owned 20,422 shares in the company, valued at $593,054.88. This represents a 26.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Edward Kaye sold 12,567 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares in the company, valued at $3,989,560.71. This trade represents a 9.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 32,916 shares of company stock valued at $1,025,302. Corporate insiders own 9.60% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the stock. Tidal Investments LLC grew its holdings in shares of Stoke Therapeutics by 16.1% during the 2nd quarter. Tidal Investments LLC now owns 9,917 shares of the company's stock valued at $324,000 after purchasing an additional 1,377 shares during the last quarter. Squarepoint Ops LLC bought a new position in Stoke Therapeutics in the 2nd quarter valued at approximately $959,000. Corient Private Wealth LP acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $1,009,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $443,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $255,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a biotechnology company focused on developing RNA-based medicines for severe genetic diseases. The company's approach is designed to increase the production of functional proteins by selectively targeting RNA splicing, a process that helps determine how genetic information is translated into proteins.

Stoke's technology is based on its TANGO platform, which uses antisense oligonucleotides to promote the inclusion of productive genetic sequences in messenger RNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.